Related Experiment Video

Updated: Jun 3, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer

Leonel F Hernandez-Aya1, Ana M Gonzalez-Angulo

  • 1Department of Internal Medicine, University of Miami Miller School of Medicine at FAU, West Palm Beach, Florida, USA.

The Oncologist
|March 17, 2011
PubMed

Insights

The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is frequently altered in breast cancer, driving cell survival and proliferation. Targeted therapies are being developed to inhibit this pathway for improved antitumor activity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The PI3K/AKT/mTOR network is crucial for cellular processes like survival, proliferation, and metabolism.
  • This pathway is frequently dysregulated in human breast cancer due to genetic aberrations, including oncogene activation and tumor suppressor inactivation.
  • AKT activation, often driven by PIK3CA mutations or PTEN loss, is a key event in breast cancer progression.

Purpose of the Study:

  • To review the fundamental biology of the PI3K/AKT/mTOR pathway.
  • To elucidate the role of this network in breast cancer development and progression.
  • To summarize the clinical evaluation of targeted therapies aimed at this pathway.

Main Methods:

  • Literature review of the PI3K/AKT/mTOR pathway's role in breast cancer.
  • Analysis of genetic aberrations commonly found in breast tumors affecting this pathway.
  • Overview of targeted therapeutic strategies and their clinical trial evaluations.

Main Results:

  • The PI3K/AKT/mTOR pathway is a central regulator of cell survival and proliferation, frequently activated in breast cancer.
  • Common genetic alterations include PIK3CA oncogene activation and PTEN tumor suppressor loss.
  • Various targeted inhibitors, including PI3K, AKT, and mTOR inhibitors, are under clinical investigation.

Conclusions:

  • The PI3K/AKT/mTOR pathway is a critical driver of breast cancer, making it a prime target for therapeutic intervention.
  • Combination strategies and broader-acting agents are being explored to overcome pathway resistance and enhance clinical efficacy.
  • Ongoing clinical trials are evaluating the potential of these targeted therapies in treating breast cancer.

More Related Videos

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures08:02

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures

Published on: July 27, 2022

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...